D isorders of insulin resistance (obesity, metabolic syndrome, and type 2 diabetes) have resulted in global demographic shifts in circulating lipid levels characterized by declining levels of low-density lipoprotein cholesterol (LDL-C).
We advocate that apolipoprotein B (apoB) is a superior measure of cardiovascular disease (CVD) risk in the modern era, during which an increasing proportion of society manifests obesity, pre-diabetes, and type 2 diabetes. Our specific arguments derive from genetics, population studies, and clinical trials.
CLINICAL MEASURES OF ATHEROGENIC

LIPIDS AND LIPOPROTEINS
The standard lipid measure for atherosclerotic CVD risk assessment LDL-C guides therapeutic interventions directed at reducing cardiovascular (CV) events. However, several lines of evidence now argue against the continued use of LDL-C as a first-line measure of lipid-related risk.
LDL-C is a calculated value that depends on the analytic variability of other directly measured components, namely total cholesterol (TC), highdensity lipoprotein cholesterol (HDL-C), and triglycerides (TGs). Specifically, LDL-C concentration is calculated as TC minus very low-density lipoprotein cholesterol (VLDL-C) (estimated as 20% of the TGs obtained after an overnight fast) minus HDL-C. In clinical laboratories, commercially available direct methods for HDL-C have a coefficient of variation in hyperlipidemia and CVD patients ranging from À19.8% to 36.3% for HDL-C and from À26.6% to 31.9% for LDL-C (1). Based on differences in CVD events at 10 years, a treatment strategy that used non-HDL-C would potentially prevent 300,000 more events than an LDL-C strategy, and an apoB strategy 500,000 more than a non-HDL-C strategy. in multivariable adjusted models that include age, race, sex and baseline smoking status, systolic blood pressure, antihypertensive medication use, body mass index, and diabetes. This discordance analysis showed that measurement of apoB at a mean age of 25 years was more predictive of CAC in 18% of these young adults than LDL-C or non-HDL-C. The high apoB groups included higher proportions of participants with high glucose, high triglycerides, and diabetes.
Additionally, the biological variability in
GENETICS
Population studies employing genome-wide association and next-generation sequencing consistently implicate loci that govern plasma LDL-C and TG levels as among the strongest determinants of CVD risk (7) . 
CLINICAL TRIALS
The placebo-controlled AFCAPS/TexCAPS study (Air
Force/Texas Coronary Atherosclerosis Prevention
Study) was the first major statin trial to report that apoB may be a better predictor of risk for major CV events than LDL-C. It found that on-treatment apoB significantly predicted risk, whereas LDL-C did not (9) . Subsequent meta-analyses have generated divergent findings. One analysis of 8 statin trials, which included both placebo-controlled studies and trials of intensive versus standard therapy, found that the predictive value of on-treatment non-HDL-C was greater than that of both apoB and LDL-C (10). A subsequent meta-analysis of 7 placebo-controlled statin trials found that RR reduction was more closely related to reductions in apoB than to reductions in either non-HDL-C or LDL-C (11). Another meta-analysis reported that among statin trials, decreases in apoB improved CHD prediction, but this observation did not extend to all cholesterollowering drug classes (12). Due to the heterogeneity in obesity and insulin resistance in these meta-analyses, it is difficult to make a definitive statement about whether apoB more accurately predicts CV risk than LDL-C or non-HDL-C.
In 
